Navigation Links
TapImmune, Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2
Date:1/30/2017

JACKSONVILLE, Fla., Jan. 30, 2017 /PRNewswire/ -- TapImmune, Inc (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that Glynn Wilson, Chief Executive Officer and Dr John Bonfiglio, Chief Operating Officer, will present live at VirtualInvestorConferences.com on February 2, 2017.

DATE: Thursday, February 2, 2017
TIME: 12:15pm Eastern Time
LINK: http://tinyurl.com/201prepr

This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register and run the online system check to save time and receive event updates.

Learn more about the event at www.VirtualInvestorConferences.com.

TapImmune Corporate Highlights

  • Potential to be dominant player in T-cell cancer vaccines by eliciting both helper and killer T-cell responses
  • Evaluating lead candidate in four Phase 2 studies, some with FDA Fast Track and Orphan Disease Status
  • Highly vetted technology: Collaborations with Mayo Clinic, AstraZeneca, Memorial Sloan Kettering Cancer Center, U.S. Dept. of Defense
  • Compelling Phase 1 data show robust and enduring immune response against vaccine targets
  • Multiple upcoming clinical value inflection points

About TapImmune, Inc.

TapImmune Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease. The Company's peptide or nucleic acid-based immunotherapeutics comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate patients' killer T-cells and helper T-cells, or to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities, including immune checkpoint inhibitors.

Please visit the Company's website at www.tapimmune.com for more details.

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-inc-to-webcast-live-at-virtualinvestorconferencescom-february-2-300398493.html


'/>"/>
SOURCE TapImmune, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. BioLight Israeli Life Sciences Investments Ltd. to Webcast, Live, at RetailInvestorConferences.com on September 12th
2. 22nd Century Group, Inc. CEO to Webcast, Live, at RetailInvestorConferences.com on December 5th
3. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com September 11
4. NW Bio To Webcast, Live, at VirtualInvestorConferences.com On May 7
5. CohBar, Inc. to Webcast, Live, at VirtualInvestorConferences.com October 1
6. Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast
7. Lightlake Therapeutics Inc. March 5th Presentation At VirtualInvestorConferences.com Now Available For On-Demand Viewing
8. Die Präsentation von Lightlake Therapeutics Inc. auf VirtualInvestorConferences.com vom 5. März steht jetzt auf Abruf zu Verfügung
9. ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7
10. Viveve to Webcast Live at VirtualInvestorConferences.com
11. DelMar Pharmaceuticals to Present an Interactive Live Webcast at VirtualInvestorConferences.com on October 1, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... ... internist, who will review how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. ... 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with ...
(Date:4/27/2017)... , April 27, 2017  Pendant Biosciences, Inc. ... innovative surface modification and drug delivery technologies, today announced ... Innovation, JLABS @ Toronto . ... Officer of Pendant Biosciences, noted, "We are excited to ... community, and are honored to be the ...
(Date:4/26/2017)... Centennial, CO (PRWEB) , ... April 25, 2017 , ... ... test offerings were added to its extensive test menu: Nucleic Acid Testing (NAT) ... that time, LABS was only able to offer NAT screening for blood donors under ...
(Date:4/25/2017)... ... ... As part of the Stago EdVantage Virtual University Virtual Event, ... order to illuminate this clinical problem for people unfamiliar with the topic. , DIC ... high degree of morbidity and mortality. DIC is a confusing disorder from both diagnostic ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):